BioSpace News Archive

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced acceptance of multiple abstracts at the European Academy of Allergy and Clinical Immunology Congress, from July 10-12, 2021.

Heat Biologics, Inc. today announced that it has been added to the Russell Microcap® Index, following the annual Russell indexes reconstitution, effective after the US market opens today, June 28, 2021, according to a final list of additions posted on June 25, 2021.

Chronolife, MedTech and service operator for the diagnosis and monitoring of chronic diseases, and the Chugai Pharma France laboratory announce a collaboration to develop a smart textile that will assess the long-term joint health of patients.

Eisai Inc. today announced the immediate appointment of Andree Amelsberg , M.D., MBA, as Vice President, U.S. Medical Affairs, Oncology Business Group.

Major advancements in medical science and technology, coupled with the increasing adoption of personalized medicine initiatives are likely to aid in expansion of the global DNA & RNA banking services market during the forecast period set between 2020 and 2030.

Ophthalmoscopes or also called direct ophthalmoscopes are hand-held optical instrument used to inspect not just fundus or back of the eye.

Increased number of research activities in all worldwide locations is projected to boost the expansion of the global polyclonal antibody market throughout the forecast period 2020–2030.

Vincerx Pharma, Inc. (Nasdaq: VINC), announced that the Company has joined the broad-market Russell 3000 and Microcap® Indexes as part of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens today, Monday, June 28, 2021.

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced the appointment of veteran biopharmaceutical leader, Scott Brun, M.D., to its Board of Directors.

Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced an update on the investigator-initiated Phase 1/2a trial of oral rigosertib plus nivolumab in advanced metastatic KRAS mutated (KRAS+) non-small cell lung cancer (NSCLC).